犬细小病毒2型变异株对高母源抗体犬的致病性

为了探究CPV-2变异株的致病性,用CPV-2a和CPV-2b野毒株,分别攻击犬细小病毒(CPV-2)高母源抗体(MDA)幼犬,根据犬临床症状,组织病理学,粪便排毒和血清抗体应答等指标,评价高母源抗体(HI滴度≥1∶160)对不同CPV病毒变异株的保护作用。结果表明, CPV-2a和CPV-2b攻毒后引起明显临床症状,攻毒后3～6 d粪便中CPV排毒。感染犬的组织样品经PCR检测表明,CPV-2a/2b病毒广泛分布。组织病理学分析表明,CPV-2a/2b感染引起肠道黏膜出血。研究表明,CPV-2高母源抗体对CPV-2a/2b变异株攻击不能提供有效保护,有必要开发CPV变异株的新型疫苗。     

犬细小病毒环介导等温扩增快速检测方法的初步建立

为建立犬细小病毒(CPV)环介导等温扩增(LAMP)检测方法,实现CPV的早期快速诊断,本研究根据GenBank登录的CPV VP2基因序列,在其序列保守区域设计LAMP引物,利用CPV基因组DNA为模板进行扩增。结果表明:LAMP方法检测灵敏度达到10-1TCID50/mL;并且与其它细小病毒等无特异性扩增,表现出良好的特异性。与PCR技术相比,LAMP法操作更加简单方便,更适合基层和实验室的快速检测。     

犬细小病毒抗体间接ELISA检测方法的建立

利用本实验室建立的昆虫细胞/杆状病毒表达系统表达犬细小病毒病毒样颗粒（CPV-VLPs）,采用硫酸铵沉淀、蔗糖密度梯度离心对表达的CPV-VLPs进行纯化,用电子显微镜、SDS-PAGE及Western-blotting方法检测纯化效果。以纯化的CPV-VLPs作为包被抗原建立CPV间接ELISA检测方法,对各反应条件进行优化并分析其特异性、敏感性、重复性。结果显示,CPV-VLPs经过纯化后纯度可达到95%以上;优化的ELISA最佳工作条件为：纯化抗原包被浓度为5.0mg/L,4℃包被过夜;1%BSA,37℃封闭2h;待检血清1∶40稀释,37℃孵育1.5h;HRP标记的酶标二抗1∶20 000稀释,37℃孵育1h;TMB室温避光显色30min;确定的血清阴性阳性临界值D450nm值为0.264。该方法可特异性检测犬细小病毒阳性血清,与犬瘟热、犬传染性肝炎、犬冠状病毒病、狂犬病阳性血清均不发生反应。该方法的敏感性为1∶640,批内重复试验变异系数小于6%,批间重复试验变异系数小于8%。42份临床血清样本的检测结果表明,与血凝抑制试验的符合率为90.48%。     

Characterisation of canine parvovirus strains isolated from cats with feline panleukopenia

Unlike the original canine parvovirus type 2 (CPV-2), CPV-2 variants have gained the ability to replicate in vivo in cats but there is limited information on the disease patterns induced by these variants in the feline host. During 2008, two distinct cases of parvoviral infection were diagnosed in our laboratories. A CPV-2a variant was identified in a 3-month-old Persian kitten displaying clinical sign of feline panleukopenia (FPL) (acute gastroenteritis and marked leukopenia) and oral ulcerations, that died eight days after the onset of the disease. Two pups living in the same pet shop as the cat were found to shed a CPV-2a strain genetically identical to the feline virus and were likely the source of infection. Also, non-fatal infection by a CPV-2c strain occurred in a 2.5-month-old European shorthair kitten displaying non-haemorrhagic diarrhoea and normal white blood cell counts. By sequence analysis of the major capsid protein (VP2) gene, the feline CPV-2c strain showed 100% identity to a recent canine type-2c isolate. Both kittens had been administered multivalent vaccines against common feline pathogens including FPL virus. Whether and to which extent the FPL vaccines can protect cats adequately from the antigenic variants of CPV-2 should be assessed.     

犬细小+犬冠状+贾第鞭毛虫抗原三合一胶体金检测卡的制备与评价

为快速检测犬细小病毒(CPV)、犬冠状病毒(CCV)和贾第鞭毛虫(Giardia),研究利用胶体金免疫层析技术制备CPV+CCV+Giardia抗原三合一胶体金检测卡并评价其各项指标.结果显示,该三合一胶体金检测卡与CDV、CPV、CAV、CRV、CCV和Giardia(自身样本除外)无交叉反应;可检测浓度低至10.0...     

口服PHA复合物对犬细小病毒疫苗免疫效果的影响

为了更好地指导犬细小病毒病的防治,减少犬患细小病毒病的几率,本文通过试验验证了PHA（植物血凝素）复合物是否对犬细小病毒疫苗有增效作用。结果表明,PHA复合物与英特威二联苗联用可提高犬对英特威二联苗的抗体应答能力,可以更好地防治犬细小病毒病。     

Occurrence of canine parvovirus type 2c in the dogs with haemorrhagic enteritis in India

Canine parvovirus 2 (CPV-2) causes a highly contagious and often fatal disease in dogs. Since its sudden emergence in the early 1970s, CPV-2 has been evolving through the generation of novel genetic and antigenic variants (CPV-2a/b/c) that are unevenly distributed throughout the world. In the present study we have examined 36 clinical cases of dogs suspected of CPV collected during year 2006. A fragment of the VP2 gene of the virus was analyzed using polymerase chain reaction (PCR), restriction endonuclease (RE) and DNA sequence analysis. Out of the 36 samples analyzed, 16 were found positive for CPV-2a/2b by conventional PCR. DNA sequencing was done for 6 PCR positive samples, out of which three were characterized as CPV-2c, indicating that this CPV type 2c is currently circulating in India.     

Expression or subcellular targeting of virus capsid proteins with cloning genome of a canine parvovirus from China

A strain of canine parvovirus (CPV), designated B2004, was isolated from the stool of a sick dog in Beijing. The partial genome (4623 bp) was cloned, sequenced with sequence showing B2004 to be a member of the widely distributed CPV-2a subclade. A completed VP2 or 11-residue N-terminal peptide (MAPPAKRARRG) of VP1 from B2004 was also tested for its ability to mediate nuclear transport of a heterologous protein, in this case enhanced green fluorescence protein (EGFP). EGFP was detected in the nucleus when it fused with the VP1 peptide; it was distributed primarily in the nucleus and also in the cytoplasm either when it fused with VP2, or in the cytoplasm when expressed on its own. In common with other parvoviruses the CPV VP1 N-terminal peptide contributes to the nuclear localization of the gene product.     

种鸡接种网状内皮组织增生病病毒弱毒疫苗的安全性和免疫效果观察

在正常饲养条件下，在肉种鸡鸡群中试用网状内皮增生病病毒（reticuloendotheliosis virus，REV）的弱毒疫苗，观察其对体重增长、产蛋生产性能、对其他疫苗应答有无影响。同时连续定期测定种鸡血清REV抗体，并测试抗体阳性鸡的后代有无病毒垂直传播。结果表明，该疫苗接种18周龄种鸡后，对生长、产蛋率、受精率和孵化率等生产性能均无不良影响，对正常疫苗免疫的抗体应答也无影响。经免疫接种REV弱毒疫苗的种鸡，在开产后及产蛋高峰期，均不表现病毒的垂直传播。免疫种鸡后，其激发的抗体可持续280d以上，且雏鸡血清中母源抗体可持续至少7d。结果表明，该REV弱毒在开产前种鸡应用时有很高的安全性，并能为雏鸡提供足够的特异性母源抗体。     

免疫程序与母源抗体对H5禽流感疫苗免疫鸭和鹅HI抗体水平的影响

对不同日龄与母源抗体水平的鸭和鹅，用H5亚型禽流感疫苗免疫后，其HI抗体消长情况进行了比较和观察，结果，初生水禽3日龄首免即可对禽流感疫苗（H5亚型）产生良好的免疫应答；雏鹅母源抗体几乎以每4d下降1个HI抗体效价单位的速度消退；母源抗体对H5禽流感疫苗免疫后的HI抗体水平存在一定的干扰作用；加强免疫鸭和鹅所产生的H5 HI抗体水平及其维持时间与仅免疫一次的鸭和鹅所产生的抗体水平之间存在显著差异；鸭和鹅免疫H5禽流感疫苗后第25～30d H5 HI抗体水平达到高峰。     

"免疫增益汤"对高母源抗体雏鸡接种ND疫苗的影响及机理研究

用具有免疫调节作用的中药组成"免疫增益汤",在含有高母源抗体(血凝抑制(HI)价在1:20以上)的雏鸡群中饮用,于5日龄用新城疫(ND)Ⅳ系疫苗点眼,然后分别于13日龄、30日龄、50日龄测定血液中HI水平,并对其作用机理进行了探讨.结果显示,免疫增益汤能显著提高NDIV系疫苗接种雏鸡的特异性HI抗体水平,并延长其持续时间.其作用机理与免疫增益汤对雏鸡免疫器官发育具有显著促进作用,且能显著增强雏鸡外周血T淋巴细胞ANAE阳性率和B淋巴细胞EAC花环率,并对雏鸡红细胞免疫粘附功能具有显著促进作用密切相关.     

Detection of rotavirus in faecal specimens with a monoclonal antibody enzyme-linked immunosorbent assay: Comparison with polyclonal antibody enzyme immuno-assays and a latex agglutination test

Monoclonal antibodies have been produced against the 81/36F strain of rotavirus. One of them, was chosen as diagnostic reagent: it showed high ELISA reactivity with all the bovine, human and porcine rotavirus strains tested and reacted with VP6, structural protein product known to support the common rotavirus antigen.

A sandwich ELISA procedure using the chosen monoclonal as “capture and detecting” antibody was performed to detect rotavirus in faecal samples from experimentally inoculated newborn calves: it always gave a negative response with meconium and a positive response for the stool specimens which rotavirus have been isolated. This assay was compared with Enzygnost and Slidex Rota Kit tests and with a non-commercial sandwich ELISA test using polyclonal antibodies: it showed more sensitivity than the agglutination test and was as sensitive as the other two tests to detect rotavirus in routine diagnostic material. The test evaluated showed no equivocal results.     

Host immune responses after administration of inactivated Venezuelan equine encephalomyelitis virus vaccines—III. Kinetics for neutralizing antibody immunoglobulin class responses in donors and adoptively-immunized recipients

C57B16 mice were immunized with either live, attenuated TC-83 strain VEE virus vaccine or formalin-inactivated VEE vaccine combined with Bordetella pertussis. The kinetics of specific donor and adoptively-immunized recipient anti-VEE neutralizing antibody responses were studied. Donor mice immunized with either live or inactivated VEE virus vaccine combined with potent adjuvants develop specific anti-VEE IgM and IgG responses as early as 7 days post-immunization. Anti-VEE IgM antibody responses comprise the majority of anti-VEE neutralizing antibody at this early time period. By 14 to 21 days post-immunization, anti-VEE IgG responses predominated. When adoptively-immunized recipients were studied, the anti-VEE IgM to IgG predominance seen in donors early after administration was reversed, and for each time-period studied, recipients' serum anti-VEE antibody class responses consisted principally of IgG rather than IgM antibody. Since T-cells cooperation with B-cells is critical in the IgM-IgG antibody shift, these studies support the critical role T-cells exert in adoptive transfer in a murine model of experimental VEE infection. Furthermore, immunization with either live or inactivated VEE vaccine coupled to a potent adjuvant induce comparable donor and adoptively-immunized recipient anti-VEE antibody class responses.     

Effect of administration of anti-bursal extract or perfusate serum on the antibody production in chickens

Antisera to bursal extracts or perfusates were prepared and the influence of such sera on antibody production in chickens was investigated by the injection of antisera during the embryonic stage. Antisera to cyclophosphamide treated bursal extracts or bursal perfusates were injected on the 15th day of embryogenesis. The level of antibodies produced by chickens treated by these antisera was equal to the controls but IgG antibodies were totally absent. These results suggested that the administration of these antisera inhibited the differentiation of IgM antibody producing cells.     

Use of a recombinant protein containing major epitopes of hnRNP G to detect anti-hnRNP G antibodies in dogs with systemic lupus erythematosus

The objective of this study was to express major epitopes of heterogeneous nuclear ribonucleoprotein G (hnRNP G) for detecting anti-hnRNP G antibodies in dogs with systemic lupus erythematosus (SLE). HnRNP G cDNA clone was isolated from HEp-2 cells, and a DNA fragment encoding immunodominant region (residues 189-272) of hnRNP G (hnRNP Gi) was subcloned into pET32 vector to construct a prokaryotic expression plasmid named pEThnRNPGi. After induction, Escherichia coli carrying pEThnRNPGi expressed a recombinant protein of 28 kDa, comprising recombinant hnRNP Gi and fusion tag. Purified recombinant hnRNP Gi protein was further analyzed by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) and its identity was confirmed. Western blot analysis showed that recombinant hnRNP Gi was specifically recognized by anti-hnRNP G positive sera of SLE dogs, and not by negative control sera. In conclusion, recombinant hnRNP Gi protein expressed in this study may serve as a useful reagent to assist in the immunological diagnosis of canine SLE.